NHS Alliance has established a partnership with Capita and diabetes leader Novo Nordisk to support the delivery of a series of strategic initiatives to drive improved integrated care and services, and help inform its activities throughout 2014 and beyond.
The Alliance is working closely with its two strategic partners, its members, and networks throughout health and social care, on large-scale projects to define new models of primary care. Work will focus on strategies for integrated services and practical work to overcome some of the barriers to the delivery of services at scale outside hospitals – moving towards a collaborative, community-based model of care.
Dr Michael Dixon, chair, NHS Alliance said: “These strategic partnerships offer the Alliance and its members expertise and support in driving forward new models of care. We believe in breaking down the historic boundaries and silos that get in the way of truly progressive and innovative community-based patient care. Forging collaborative partnerships both inside and outside the public sector is a natural and essential extension of this.”
Neil Griffiths, health market director at Capita said: “Capita is delighted to work with the NHS Alliance and support its focus on primary and out-of-hospital care. As with all our partnerships, we will seek to offer our experience of technology, service transformation and user-centred design in support of their mission to improve services and do their very best for each and every patient.”
Peter Meeus, managing director, Novo Nordisk UK, said: “At Novo Nordisk, we believe in changing diabetes through collaboration and making a real difference for our patients by forging long-lasting, strategic partnerships. We are proud to join forces with the NHS Alliance to help create an environment in which people living with diabetes receive the comprehensive care and support they need to achieve positive health outcomes.”
A “Beyond Boundaries” working group took place on June 19, to define the practical issues facing practices as they undertake the challenge of providing extended care and the motivations for them to do so. The working group included clinicians, providers and advisors from a wide group of organisations actively working in primary care.
This was followed by a roundtable discussion at The Commissioning Show, one of the largest ever gatherings of health professionals (June 25), to identify the learnings for integrated care from models operating overseas. The objective of both these groups is to propose a more detailed model of how general practice can be developed at scale. The aim is to engender a move from a system that simply permits general practice at scale to one that encourages, enables and supports CCGs and GP practices and wider primary care providers to progress this rapidly and comprehensively as part of creating a sustainable NHS.
On November 14, 2014, World Diabetes Day, NHS Alliance will be partnering with Novo Nordisk to jointly host The Diabetes Exchange Summit. Focusing on bringing innovation into practice, the Summit will bring together over a hundred commissioners, providers and people with diabetes to stimulate collaboration and help build a patient-centred NHS.
NHS Alliance is the leading independent voice for providers of health and social care outside hospital. It is the only not-for-profit membership organisation to bring together frontline clinicians and organisations of all kinds in our communities – from general practice, community pharmacy to providers of housing and emergency services.
It is driving a new integrated and collaborative, community-based model of care for an ageing population living with long term conditions, and is focused on breaking down the historic boundaries and silos that get in the way of truly progressive and innovative community-based patient care.
For more information visit www.thehealthcreationalliance.org
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.co.uk.
Capita plc is the UK’s leading provider of BPO and integrated professional support service solutions. With 62,000 people at more than 350 sites, including 70 business centres across the UK, Europe, India and South Africa, the Group uses its expertise, infrastructure and scale benefits to transform its clients’ services, driving down costs and adding value. Capita is quoted on the London Stock Exchange (CPI.L), and is a constituent of the FTSE 100 with 2012 revenue of £3.3 billion. Further information on Capita plc can be found at: www.capita.co.uk